Back to Atlas
CTransientStandard research/education caution
CMP-0739
Research chemical/reference listing
Chymostatin
Immune modulation
Immune balance, inflammation, or resilience support
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Immune / inflammatory modulator
- Primary mechanism
- Immune or inflammatory pathway modulation
- Primary market use
- Immune modulation
Pharmacology
- Molecular weight (Da)
- 607.70
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~2–12 h small-molecule class estimate
- Route tags
- Route-dependent / verify
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 5 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Chymostatin is a SARS-CoV-2 M pro inhibitor. Chymostatin up-regulates endocan and inhibits NF-κBp65 activity. Chymostatin reduces proinflammatory cytokines ( IL-1β and IL-6 ) and HMGB1 . Chymostatin shows protective effects against Paraquat-induced acute lung injury. Chymostatin exhibits anticancer activity against lung cancer .